THOUSAND OAKS, Calif., Jan. 31, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from earlier today.
The transcript, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Audio of the webcast will also be archived and available for replay for at least 90 days after the event.
CONTACT: Amgen, Thousand Oaks
Jessica Akopyan, 805-447-0974 (media)
Megan Fox, 805-447-1423 (media)
Arvind Sood, 805-447-1060 (investors)
| Last Trade: | US$264.21 |
| Daily Change: | 2.15 0.82 |
| Daily Volume: | 1,568,619 |
| Market Cap: | US$142.020B |
January 08, 2025 December 05, 2024 December 02, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
